College of Life Science and Technology, Guangxi University, Nanning, 530004, China.
Medical College, Guangxi University, Nanning, 530004, China.
Biosens Bioelectron. 2022 May 15;204:114083. doi: 10.1016/j.bios.2022.114083. Epub 2022 Feb 10.
In this work, three novel dual-targeting fluorescent probes were designed with modification by imidazole and one galactose (IM-Gal-1), by imidazole and two galactoses (IM-Gal-2), and by imidazole and three galactoses (IM-Gal-3), separately. These probes showed good selectivity and sensitivity toward Fe with 1:2 stoichiometry recognition mode. The detection limits toward Fe were (1.293 ± 0.005) × 10 M for IM-Gal-1, (7.735 ± 0.005) × 10 M for IM-Gal-2, and (1.325 ± 0.023) × 10 M for IM-Gal-3. These low-toxic probes exhibited excellent hepatic targeting capacity, which is attributed to the specific recognition of asialoglycoprotein receptor (ASGPR) overexpressed on hepatocytes by the galactose group of probes. The hepatic targeting capacity followed IM-Gal-1 < IM-Gal-2< IM-Gal-3 trend due to the galactose cluster effect. Under the attraction between acidic lysosome and basic imidazole group, these imidazole-modified probes were confirmed to possess good lysosome-targeting capacities, earlier demonstrating imidazole as a lysosome-targeting group. Overall, these dual-targeting probes co-modified by galactose and imidazole exhibited unique advantages in precise diagnosis and treatment of liver lysosomal iron-related diseases.
在这项工作中,分别通过咪唑和一个半乳糖(IM-Gal-1)、咪唑和两个半乳糖(IM-Gal-2)以及咪唑和三个半乳糖(IM-Gal-3)的修饰,设计了三种新型的双重靶向荧光探针。这些探针对 Fe 具有良好的选择性和灵敏度,识别模式为 1:2 化学计量比。IM-Gal-1、IM-Gal-2 和 IM-Gal-3 对 Fe 的检测限分别为(1.293±0.005)×10-7 M、(7.735±0.005)×10-7 M 和(1.325±0.023)×10-7 M。这些低毒性探针表现出优异的肝靶向能力,这归因于探针上的半乳糖基团对肝细胞上过度表达的去唾液酸糖蛋白受体(ASGPR)的特异性识别。由于半乳糖簇效应,肝靶向能力呈现出 IM-Gal-1<IM-Gal-2<IM-Gal-3 的趋势。在酸性溶酶体和碱性咪唑基团之间的吸引力作用下,这些咪唑修饰的探针被证实具有良好的溶酶体靶向能力,首次证明咪唑是一种溶酶体靶向基团。总的来说,这些同时被半乳糖和咪唑双重修饰的双重靶向探针在肝溶酶体铁相关疾病的精确诊断和治疗中具有独特的优势。